Sanofi announced positive results from PRIME, a second phase 3 trial of evaluating Dupixent (dupilumab) in adults with uncontrolled prurigo nodularis, a chronic type 2 inflammatory…
Aldeyra Therapeutics announced positive top-line data from a Phase 2 clinical trial comparing reproxalap ophthalmic solution 0.25% (reproxalap) versus Novartis’ Xiidra (lifitegrast ophthalmic solution 5%),…
Mesoblast presented 36-month follow-up results from a Phase 3 trial of its allogeneic cell therapy rexlemestrocel-L (MPC-06-ID) in patients with chronic low back pain (CLBP)…
ObsEva announced positive topline results from the Phase 3 EDELWEISS 3 trial of linzagolix, an oral GnRH antagonist, in women with moderate-to-severe endometriosis-associated pain (EAP).…
Pluristem announced topline results from its Phase II dose escalation studies evaluating the safety and efficacy of intramuscular injections of PLXPAD cells for the treatment…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
